Difference between revisions of "Team:SYSU-MEDICINE"

Line 70: Line 70:
 
             color: #999;
 
             color: #999;
 
             font-weight:600;
 
             font-weight:600;
 +
        }
 +
        .navbar-nav>li{
 +
            top: -5px;
 
         }
 
         }
 
         /*.mw-content-ltr ul, .mw-content-rtl .mw-content-ltr ul {*/
 
         /*.mw-content-ltr ul, .mw-content-rtl .mw-content-ltr ul {*/
Line 286: Line 289:
 
                 canHide = true;
 
                 canHide = true;
 
             });
 
             });
−
             $(".third-level-list").css("left", "150px");
+
             $(".third-level-list").css("left", "100px");
 
//          third level menu on nav
 
//          third level menu on nav
 
             $(".third-level-menu").mouseenter(function() {
 
             $(".third-level-menu").mouseenter(function() {
Line 297: Line 300:
 
                 $(this).removeClass("open");
 
                 $(this).removeClass("open");
 
             });
 
             });
−
 
+
            $(".dropdown").mouseenter(function() {
 +
                $(this).addClass("open");
 +
            });
 +
            $(".dropdown").mouseleave(function() {
 +
                $(this).removeClass("open");
 +
            });
 
         });
 
         });
 
     </script>
 
     </script>

Revision as of 15:13, 12 October 2016

MSCavalry

-----MSCs of
next generation

Inflammatory diseases are an increasing cause of disability and even fatality. Currently, apart from common treatments, MSCs therapy is a promising candidate for curing inflammatory diseases. However, intravascular injected MSCs are criticized for its low homing efficiency and ambiguous distribution in human body.

This year, MSCavalry: MSCs of next generation is coming. SYSU-MEDICINE decide to engineer a set of MSCs (homo sapiens) with higher accuracy and we hope that our project can pave the way for future MSCs clinical application.